{
    "clinical_study": {
        "@rank": "25328", 
        "arm_group": {
            "arm_group_label": "Treatment (imatinib mesylate)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive oral imatinib mesylate daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients within each stratum (except normal stratum) receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity"
        }, 
        "brief_summary": {
            "textblock": "Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they\n      stop growing or die. Phase I trial to study the effectiveness of imatinib mesylate in\n      treating patients who have advanced cancer and liver dysfunction"
        }, 
        "brief_title": "Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction", 
        "condition": [
            "Accelerated Phase Chronic Myelogenous Leukemia", 
            "Acute Undifferentiated Leukemia", 
            "AIDS-related Peripheral/Systemic Lymphoma", 
            "AIDS-related Primary CNS Lymphoma", 
            "Anaplastic Large Cell Lymphoma", 
            "Angioimmunoblastic T-cell Lymphoma", 
            "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", 
            "Blastic Phase Chronic Myelogenous Leukemia", 
            "Childhood Myelodysplastic Syndromes", 
            "Chronic Eosinophilic Leukemia", 
            "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", 
            "Chronic Myelomonocytic Leukemia", 
            "Chronic Neutrophilic Leukemia", 
            "Chronic Phase Chronic Myelogenous Leukemia", 
            "de Novo Myelodysplastic Syndromes", 
            "Essential Thrombocythemia", 
            "Extramedullary Plasmacytoma", 
            "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", 
            "Gastrointestinal Stromal Tumor", 
            "Intraocular Lymphoma", 
            "Isolated Plasmacytoma of Bone", 
            "Meningeal Chronic Myelogenous Leukemia", 
            "Monoclonal Gammopathy of Undetermined Significance", 
            "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", 
            "Nodal Marginal Zone B-cell Lymphoma", 
            "Polycythemia Vera", 
            "Previously Treated Myelodysplastic Syndromes", 
            "Primary Central Nervous System Non-Hodgkin Lymphoma", 
            "Primary Myelofibrosis", 
            "Primary Systemic Amyloidosis", 
            "Progressive Hairy Cell Leukemia, Initial Treatment", 
            "Prolymphocytic Leukemia", 
            "Recurrent Adult Acute Lymphoblastic Leukemia", 
            "Recurrent Adult Acute Myeloid Leukemia", 
            "Recurrent Adult Burkitt Lymphoma", 
            "Recurrent Adult Diffuse Large Cell Lymphoma", 
            "Recurrent Adult Diffuse Mixed Cell Lymphoma", 
            "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", 
            "Recurrent Adult Hodgkin Lymphoma", 
            "Recurrent Adult Immunoblastic Large Cell Lymphoma", 
            "Recurrent Adult Lymphoblastic Lymphoma", 
            "Recurrent Adult T-cell Leukemia/Lymphoma", 
            "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", 
            "Recurrent Grade 1 Follicular Lymphoma", 
            "Recurrent Grade 2 Follicular Lymphoma", 
            "Recurrent Grade 3 Follicular Lymphoma", 
            "Recurrent Mantle Cell Lymphoma", 
            "Recurrent Marginal Zone Lymphoma", 
            "Recurrent Mycosis Fungoides/Sezary Syndrome", 
            "Recurrent Small Lymphocytic Lymphoma", 
            "Refractory Chronic Lymphocytic Leukemia", 
            "Refractory Hairy Cell Leukemia", 
            "Refractory Multiple Myeloma", 
            "Relapsing Chronic Myelogenous Leukemia", 
            "Secondary Acute Myeloid Leukemia", 
            "Secondary Myelodysplastic Syndromes", 
            "Small Intestine Lymphoma", 
            "Splenic Marginal Zone Lymphoma", 
            "Stage IV Adult Burkitt Lymphoma", 
            "Stage IV Adult Diffuse Large Cell Lymphoma", 
            "Stage IV Adult Diffuse Mixed Cell Lymphoma", 
            "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", 
            "Stage IV Adult Hodgkin Lymphoma", 
            "Stage IV Adult Immunoblastic Large Cell Lymphoma", 
            "Stage IV Adult Lymphoblastic Lymphoma", 
            "Stage IV Adult T-cell Leukemia/Lymphoma", 
            "Stage IV Chronic Lymphocytic Leukemia", 
            "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", 
            "Stage IV Grade 1 Follicular Lymphoma", 
            "Stage IV Grade 2 Follicular Lymphoma", 
            "Stage IV Grade 3 Follicular Lymphoma", 
            "Stage IV Mantle Cell Lymphoma", 
            "Stage IV Marginal Zone Lymphoma", 
            "Stage IV Mycosis Fungoides/Sezary Syndrome", 
            "Stage IV Small Lymphocytic Lymphoma", 
            "T-cell Large Granular Lymphocyte Leukemia", 
            "Unspecified Adult Solid Tumor, Protocol Specific", 
            "Untreated Adult Acute Lymphoblastic Leukemia", 
            "Untreated Adult Acute Myeloid Leukemia", 
            "Untreated Hairy Cell Leukemia", 
            "Waldenstr\u00f6m Macroglobulinemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "Primary Myelofibrosis", 
                "Amyloidosis", 
                "Blast Crisis", 
                "Burkitt Lymphoma", 
                "Neoplasms", 
                "Hodgkin Disease", 
                "Immunoblastic Lymphadenopathy", 
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Hairy Cell", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myeloid, Accelerated Phase", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Leukemia, Myeloid, Chronic-Phase", 
                "Leukemia, Myelomonocytic, Chronic", 
                "Leukemia, Neutrophilic, Chronic", 
                "Leukemia, Prolymphocytic", 
                "Leukemia, T-Cell", 
                "Leukemia-Lymphoma, Adult T-Cell", 
                "Lymphoma", 
                "Lymphoma, Follicular", 
                "Lymphoma, Non-Hodgkin", 
                "Waldenstrom Macroglobulinemia", 
                "Monoclonal Gammopathy of Undetermined Significance", 
                "Paraproteinemias", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell", 
                "Mycoses", 
                "Mycosis Fungoides", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Leukemia, Myelomonocytic, Acute", 
                "Myeloproliferative Disorders", 
                "Plasmacytoma", 
                "Polycythemia", 
                "Polycythemia Vera", 
                "Sezary Syndrome", 
                "Thrombocythemia, Essential", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse", 
                "Lymphoma, Large-Cell, Immunoblastic", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Cutaneous", 
                "Liver Diseases", 
                "Hypereosinophilic Syndrome", 
                "Lymphoma, Large-Cell, Anaplastic", 
                "Gastrointestinal Stromal Tumors", 
                "Lymphoma, B-Cell, Marginal Zone", 
                "Lymphoma, Mantle-Cell", 
                "Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative", 
                "Thrombocytosis", 
                "Myelodysplastic-Myeloproliferative Diseases", 
                "Leukemia, Large Granular Lymphocytic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Determine the maximum tolerated dose and dose-limiting toxicity of imatinib mesylate in\n      patients with advanced malignancies and varying degrees of liver dysfunction.\n\n      II. Determine the effects of hepatic dysfunction on the pharmacodynamics and\n      pharmacokinetics of this drug in these patients.\n\n      III. Determine the non-dose-limiting toxic effects of this drug in these patients.\n\n      IV. Determine the response rate of these patients treated with this drug. V. Correlate the\n      Childs-Pugh classification of hepatic dysfunction with observed toxic effects,\n      pharmacodynamics, and pharmacokinetics of this drug in these patients.\n\n      OUTLINE: This is a dose-escalation, multicenter study.  Patients are stratified according to\n      liver dysfunction (normal vs mild vs moderate vs severe).\n\n      Patients receive oral imatinib mesylate daily. Courses repeat every 4 weeks in the absence\n      of disease progression or unacceptable toxicity. Cohorts of 3-6 patients within each stratum\n      (except normal stratum) receive escalating doses of imatinib mesylate until the maximum\n      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2\n      of 3 or 2 of 6 patients experience dose-limiting toxicity.\n\n      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study within 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed surgically incurable solid tumor\n             orhematologic malignancy for which no standard or palliative therapy exists oris no\n             longer effective\n\n               -  All tumor types are eligible, including:\n\n                    -  Chronic myelogenous leukemia or other Philadelphia chromosome-positive\n                       leukemia OR\n\n                    -  Gastrointestinal stromal tumors\n\n          -  Patients with gliomas that require corticosteroids or anticonvulsants must beon a\n             stable dose and seizure-free for 1 month\n\n          -  No unstable or untreated (non-irradiated) brain metastases\n\n          -  Performance status - ECOG 0-2\n\n          -  Performance status - Karnofsky 60-100%\n\n          -  More than 3 months\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n          -  No active hemolysis\n\n          -  See Surgery\n\n          -  No evidence of biliary sepsis\n\n          -  Creatinine normal\n\n          -  Creatinine clearance at least 60 mL/min\n\n          -  No symptomatic congestive heart failure\n\n          -  No unstable angina pectoris\n\n          -  No cardiac arrhythmia\n\n          -  Able to swallow pills\n\n          -  No other uncontrolled concurrent illness that would preclude study participation\n\n          -  No ongoing or active infection\n\n          -  No uncontrolled diarrhea\n\n          -  No psychiatric illness or social situation that would preclude study compliance\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective barrier contraception during and for 6 months\n             after study completion\n\n          -  At least 24 hours since prior colony-stimulating factors\n\n          -  No concurrent colony-stimulating factors\n\n          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and\n             recovered\n\n          -  See Disease Characteristics\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n          -  See Disease Characteristics\n\n          -  At least 10 days since prior placement of shunt for treatment of biliary obstruction\n\n          -  At least 14 days since prior major surgery\n\n          -  No prior solid organ transplantation\n\n          -  No other concurrent investigational agents\n\n          -  No concurrent therapeutic doses of warfarin for anticoagulation\n\n          -  No other concurrent investigational or commercial agents or therapies for treatment\n             of this disease\n\n          -  No concurrent combination antiretroviral therapy for HIV-positive patients\n\n          -  No concurrent acetaminophen of more than 4,000 mg/day"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 11, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT00025948", 
            "nct_id": "NCT00025415", 
            "org_study_id": "NCI-2012-02418", 
            "secondary_id": [
                "01-028", 
                "U01CA099168", 
                "U01CA062505", 
                "U01CA062491", 
                "U01CA062502", 
                "U01CA062487", 
                "CDR0000068959"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (imatinib mesylate)", 
                "description": "Given orally", 
                "intervention_name": "imatinib mesylate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CGP 57148", 
                    "Gleevec", 
                    "Glivec"
                ]
            }, 
            {
                "arm_group_label": "Treatment (imatinib mesylate)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Imatinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15232"
                }, 
                "name": "University of Pittsburgh"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction", 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "Ramesh Ramanathan", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "MTD defined based on the toxicities observed during the first  cycle of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Results will be tabulated by liver dysfunction group.", 
                "measure": "Toxicity evaluation graded according to the NCI common toxicity criteria and relationship to the study drug", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00025415"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Will be analyzed with ADAPT II, and results will be summarized separately for the four study groups.  Additionally, results for pharmacokinetic parameters will be related to the measured level of liver dysfunction in exploratory analyses.", 
                "measure": "Pharmacokinetic data", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 2, 3, 4, 15, 16"
            }, 
            {
                "description": "Will be tabulated by liver dysfunction group, and by dose if appropriate.", 
                "measure": "Responses", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "description": "Will be correlated to the toxicities, pharmacokinetic and pharmacodynamic data seen with STI571.", 
                "measure": "Child-Pugh Classification", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 2001", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }, 
    "geocoordinates": {
        "University of Pittsburgh": "40.441 -79.996"
    }
}